Clinical efficacy and safety of erlotinib combined with chemotherapy in the treatment of advanced pancreatic cancer: A meta-analysis

Table 1 Baseline characteristics of studies included in the meta-analysis

Ref.	Vintages	Number of examples		M/F		Age/yr		Intervention		Observation indicators
		Control patients	Research group	Control patients	Research group	Control patients	Research group	Control patients	Research group
Takahashi et al[9]	2014	202	102	-	-	-	-	Gemcitabine (loanword)	Gemcitabine + erlotinib	1, 2, 3
Wang et al[10]	2015	44	44	33/11	32/12	-	-	Gemcitabine (loanword)	Gemcitabine + erlotinib	1, 2, 3
Moore et al[11]	2007	284	285	162-122	136/149	64 (36.1–92.4)	63.7 (37.9–84.4)	Gemcitabine + placebo	Gemcitabine + Erlotinib	1, 2, 3
Hammel et al[12]	2016	223	219	117/106	111/108	64 (57–70)	63 (58–71)	Gemcitabine (loanword)	Gemcitabine + erlotinib	2, 3, 4, 6, 7
Jeon et al[13]	2012	19	34	14/5	20/14	58 (48–70)	59.5 (35–73)	Gemcitabine + capecitabine	Gemcitabine + erlotinib	1, 2, 3, 4, 5 ,6, 8
Abrams et al[14]	2020	163	167	88/75	96/63	-	-	Gemcitabine (loanword)	Gemcitabine + erlotinib	2, 3
Sinn et al[15]	2017	217	219	119/98	128/91	65 (24–82)	63 (28–82)	Gemcitabine (loanword)	Gemcitabine + erlotinib	2, 3
Lim et al[16]	2015	36	44	25/11	25/19	68 (41–84)	63 (32–78)	Gemcitabine + capecitabine	Gemcitabine + erlotinib	1, 2, 3, 4, 5, 6, 7, 8
Halfdanarson et al[17]	2019	46	46	29/17	31/15	Median age: 60.5	Median age: 62	Gemcitabine (loanword)	Gemcitabine + erlotinib	2, 3, 5, 6, 7
Chun et al[18]	2011	18	26	-	-	Median age: 57.67 years	Median age: 56.58 years	Gemcitabine + capecitabine	Gemcitabine + erlotinib	2, 3

1: Disease control rate; 2: Overall survival; 3: Progression-free survival; 4: Diarrhea; 5: Skin rash; 6: Vomiting; 7: Regurgitation/anorexia; 8: Infection.